Butyl lactate emulsions for the precipitation of water-insoluble drug nanoparticles
View Patent ↗Emulsions for use in precipitating water-insoluble drug nanoparticles. The continuous phase of the emulsions include water and an external surfactant. The discontinuous phase of the emulsions include butyl lactate, a co-solvent, an internal surfactant and a water-insoluble drug that is solubilized in the discontinuous phase. The emulsions allow for the precipitation of nanoparticles of water-insoluble drugs that are otherwise difficult or impossible to precipitate using conventional emulsion techniques.
1. An emulsion for use in precipitating water-insoluble drug nanoparticles, the emulsion comprising:
from about 50% to about 95% by weight of a continuous phase comprising:
water; and
an external surfactant in an amount not greater than about 50% by weight of the continuous phase; and
from about 5% to about 50% by weight of a discontinuous phase comprising:
butyl lactate;
an internal surfactant;
a water-insoluble drug in an amount not greater than about 50% by weight of the discontinuous phase, wherein the water-insoluble drug is solubilized in the discontinuous phase, and wherein the weight ratio of the internal surfactant to the water-insoluble drug is from about 1:1to about 10:1; and
a co-solvent selected from the group consisting of C6to C10 straight-chain alkanes, dichloromethane, chloroform and C 1 -C 4 linear alcohols, said co-solvent being present in an amount sufficient to solubilize the water-insoluble drug and/or the internal surfactant in the butyl lactate and thereby form an organic solution that forms the entire discontinuous phase of the emulsion.
2. An emulsion for use in precipitating water-insoluble drug nanoparticles, the emulsion comprising:
from about 70% to about 90% by weight of a continuous phase comprising:
water; and
from about 1to about 5% by weight of the continuous phase of an external surfactant selected from the group consisting of polysorbate-80, pluronic, poly vinyl alcohol (PVA), poly ethylene glycol and tocopherol acetate; and
from about 10% to about 30% by weight of a discontinuous phase comprising:
butyl lactate;
an internal surfactant;
from about 2% to about 10% by weight of the discontinuous phase of a water-insoluble drug that is solubilized in the discontinuous phase, and wherein the weight ratio of the internal surfactant to the water-insoluble drug is from about 1:1to about 4:1; and
a co-solvent selected from the group consisting of hexane and dichloromethane, said co-solvent being present in an amount sufficient to solubilize the water-insoluble drug and/or the internal surfactant in the butyl lactate and thereby form an organic solution that forms the entire discontinuous phase of the emulsion.
3. A method of producing nanoparticles of a water-insoluble drug, the method comprising:
providing an emulsion comprising:
from about 50% to about 95% by weight of a continuous phase comprising:
water; and
an external surfactant in an amount not greater than about 50% by weight of the continuous phase; and
from about 5% to about 50% by weight of a discontinuous phase comprising:
butyl lactate;
an internal surfactant;
a water-insoluble drug in an amount not greater than about 50% by weight of the discontinuous phase, wherein the water-insoluble drug is solubilized in the discontinuous phase, and wherein the weight ratio of the internal surfactant to the water-insoluble drug is from about 1:1 to about 10:1;and
a co-solvent selected from the group consisting of C6 to C10 straight-chain alkanes, dichloromethane, chloroform and C 1 -C 4 linear alcohols, said co-solvent being present in an amount sufficient to solubilize the water-insoluble drug and/or the internal surfactant in the butyl lactate and thereby form an organic solution that forms the entire discontinuous phase of the emulsion; and
extracting at least the butyl lactate and the co-solvent from the discontinuous phase of the emulsion using a supercritical fluid to precipitate nanoparticles of the water-insoluble drug and thereby form an aqueous suspension of water-insoluble drug nanoparticles.